Evidence profile
Tesamorelin
Tesamorelin study rows link each listed finding to its source, model or population, and endpoint.
Cited headline finding
The trial reported a −15.2% CT visceral-adipose-tissue change compared with +5.0% for placebo. ↗
412 HIV-positive adults with abdominal-fat accumulationFalutz et al., NEJM 2007Phase 3
Mechanism scope
How cited research characterizes Tesamorelin
The cited Tesamorelin trials report CT-measured visceral-adipose-tissue outcomes in defined HIV populations.
Sources: Falutz et al., NEJM 2007 ↗ · Falutz et al., JCEM 2010 ↗
Open question
What the cited Tesamorelin sources do not resolve
The cited Tesamorelin trials do not establish outcomes outside their stated HIV populations and endpoints.
Sources: Falutz et al., NEJM 2007 ↗ · Falutz et al., JCEM 2010 ↗
| Finding | Year | n | Model or population | Endpoint | Source | Evidence tier |
|---|---|---|---|---|---|---|
| The pooled Phase 3 study reported sustained visceral-adipose-tissue reduction. | 2010 | 806 | 806 adults receiving antiretroviral therapy | Visceral-adipose-tissue change | Falutz et al., JCEM 2010 ↗ | Phase 3 |
| The trial reported a −15.2% CT visceral-adipose-tissue change compared with +5.0% for placebo. | 2007 | 412 | 412 HIV-positive adults with abdominal-fat accumulation | CT visceral-adipose-tissue change | Falutz et al., NEJM 2007 ↗ | Phase 3 |
Regulatory status
Tesamorelin appears in FDA prescribing information for EGRIFTA WR. ↗
Reviewer: Ember Peptides source-verification editorial review · Review date: 2026-09-13